



Skin Cancer: Recent Advances in Diagnosis, Treatment, and Prevention

Guest Editor:

Prof. Dr. Alexander Kreuter

1. Department of Dermatology,
Venereology and Allergology,
Helios St. Elisabeth Hospital
Oberhausen, University
Witten/Herdecke, 46045
Oberhausen, Germany
2. Department of Dermatology,
Venereology and Allergology,
Helios St. Johannes Hospital
Duisburg, 47166 Duisburg,
Germany

Deadline for manuscript
submissions:
closed (31 December 2023)

Message from the Guest Editor

Skin cancer is by far the most common malignancy worldwide, affecting men and women of every skin color. The incidence of both melanoma and non-melanoma skin cancer (keratinocyte skin cancer such as basal cell carcinoma and squamous cell carcinoma) has increased in recent decades. According to the World Health Organisation (WHO), between 2 and 3 million non-melanoma skin cancers and approximately 132,000 melanoma skin cancers are diagnosed globally each year. One in every three cancers diagnosed annually is a skin cancer.

Tremendous progress has been achieved in recent years in the understanding of the molecular pathogenesis of skin cancer, leading to the development of new therapeutic strategies. In the last decade, there has been a paradigm shift in how we approach the treatment of skin cancer, especially advanced melanoma, due to the unprecedented success of MAPK pathway and immune checkpoint inhibitors. The latter have revolutionized the treatment landscape of many hematological and solid tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)